Starting from the results of these two well-documented trials, which suggest that SGLT2 inhibitors exhibit a positive role in the natural evolution of heart failure and CKD, we set out to clarify which is the potential pathogenetic mechanism that leads to the observed treatment effects. This evidence concerns the gene SLC5A2 and chronic kidney disease.